Results 11 to 20 of about 35,970 (259)

Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis

Open Heart
Aim Anakinra, an anti IL-1 agent targeting IL-1 alfa and beta, is available for the treatment of recurrent pericarditis in cases with corticosteroid dependence and colchicine resistance after failure of conventional therapies.
Allan L Klein, Antonio Abbate, Massimo Imazio, George Lazaros, Antonio Brucato, Luca Cantarini, Marco Merlo, Gianfranco Sinagra, Alessandro Andreis, Valentino Collini, Maria De Martino, Marzia De Biasio, Miriam Isola, Nicole Croatto, Veronica Lepre   +14 more
doaj   +2 more sources

Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19

Frontiers in Pediatrics, 2022
ObjectiveThe study aimed to report the efficacy and safety of anakinra treatment in patients with the refractory multisystemic inflammatory syndrome in children (MIS-C).MethodsThis is a cross-sectional retrospective study consisting of pediatric patients
Şengül Çaǧlayan, Hafize Emine Sönmez, Gülçin Otar Yener, Esra Baǧlan, Kübra Öztürk, Kadir Ulu, Vafa Guliyeva, Demet Demirkol, Mustafa Çakan, Semanur Özdel, Hulya Bukulmez, Nuray Aktay Ayaz, Betül Sözeri   +12 more
doaj   +2 more sources

Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis

European Journal of Medical Research, 2023
Background At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen ...
Karolina Dahms, Agata Mikolajewska, Kelly Ansems, Maria-Inti Metzendorf, Carina Benstoem, Miriam Stegemann   +5 more
doaj   +2 more sources

Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study

Frontiers in Pediatrics, 2023
BackgroundThe treatment of multisystem inflammatory syndrome in children unresponsive to first-line therapies (IVIG and/or steroids) is challenging. The effectiveness of IL-1 receptor antagonist, anakinra, is debated.Patients and methodsWe conducted an ...
Francesco Licciardi, Carlotta Covizzi, Marta Dellepiane, Nicole Olivini, Maria Vincenza Mastrolia, Andrea Lo Vecchio, Viviana Monno, Maria Tardi, Angela Mauro, Maria Alessio, Giovanni Filocamo, Marco Cattalini, Andrea Taddio, Roberta Caorsi, Gian Luigi Marseglia, Francesco La Torre, Andrea Campana, Gabriele Simonini, Angelo Ravelli, Davide Montin   +19 more
doaj   +2 more sources

Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) [PDF]

Journal for ImmunoTherapy of Cancer, 2022
In addition to remarkable antitumor activity, chimeric antigen receptor (CAR) T-cell therapy is associated with acute toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Current treatment
Marc Wehrli, Kathleen Gallagher, Yi‐Bin Chen, Mark B. Leick, Steven L. McAfee, Areej El‐Jawahri, Zachariah DeFilipp, Nora Horick, Paul V. O’Donnell, Thomas R. Spitzer, Bimal Dey, Daniella Cook, Michael Trailor, Kevin Lindell, Marcela V. Maus, Matthew J. Frigault   +15 more
openalex   +2 more sources

Anakinra Pilot – a clinical trial to demonstrate safety, feasibility and pharmacokinetics of interleukin 1 receptor antagonist in preterm infants

Frontiers in Immunology, 2022
BackgroundBronchopulmonary dysplasia (BPD), its complication pulmonary hypertension (BPD-PH) and preterm brain and gut injury lead to significant morbidity and mortality in infants born extremely prematurely.
Elys A. Green, Elys A. Green, Elys A. Green, David Metz, David Metz, David Metz, Robert Galinsky, Rebecka Atkinson, Rebecka Atkinson, Elizbeth M. Skuza, Megan Clark, Megan Clark, Alistair J Gunn, Carl M. Kirkpatrick, Rod W. Hunt, Rod W. Hunt, Rod W. Hunt, Philip J. Berger, Claudia A. Nold-Petry, Claudia A. Nold-Petry, Marcel F. Nold, Marcel F. Nold, Marcel F. Nold   +22 more
doaj   +2 more sources

Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome

ACR Open Rheumatology, 2020
Objective The objective of this study was to report the benefit of a therapeutic approach consisting of intravenous (IV) continuous anakinra (recombinant human interleukin‐1 receptor antagonist) infusions in treating severely ill adult patients with ...
Luke Adam Monteagudo, Aaron Boothby, Elie Gertner   +2 more
doaj   +2 more sources

Anakinra and dexamethasone treatment of idarubicin‐induced mucositis and diarrhoea in rats [PDF]

Basic & Clinical Pharmacology & Toxicology, 2023
Chemotherapy‐induced mucositis, characterized by diarrhoea and villous atrophy, is a severe side effect contributing to reduced quality of life and premature death in cancer patients treated with cytostatics.
Fredrik Kullenberg, Karsten Peters, Markus Sjöblom, Femke Heindryckx, David Dahlgren, Hans Lennernäs   +5 more
openalex   +2 more sources

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Nature Network Boston, 2021
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to respiratory failure.
E. Kyriazopoulou, G. Poulakou, H. Milionis, S. Metallidis, G. Adamis, K. Tsiakos, A. Fragkou, A. Rapti, Christina Damoulari, M. Fantoni, I. Kalomenidis, G. Chrysos, A. Angheben, I. Kainis, Z. Alexiou, F. Castelli, F. Serino, M. Tsilika, P. Bakakos, E. Nicastri, V. Tzavara, E. Kostis, L. Dagna, Panagiotis Koufargyris, K. Dimakou, S. Savvanis, G. Tzatzagou, M. Chini, G. Cavalli, M. Bassetti, K. Katrini, V. Kotsis, G. Tsoukalas, C. Selmi, I. Bliziotis, M. Samarkos, M. Doumas, S. Ktena, A. Masgala, I. Papanikolaou, M. Kosmidou, D. Myrodia, A. Argyraki, C. Cardellino, K. Koliakou, E. Katsigianni, V. Rapti, E. Giannitsioti, A. Cingolani, S. Micha, Karolina Akinosoglou, Orestis Liatsis-Douvitsas, S. Symbardi, N. Gatselis, M. Mouktaroudi, G. Ippolito, E. Florou, A. Kotsaki, M. Netea, J. Eugen-Olsen, M. Kyprianou, P. Panagopoulos, G. Dalekos, E. Giamarellos‐Bourboulis   +63 more
semanticscholar   +1 more source

Intravenous administration of anakinra in children with macrophage activation syndrome

Pediatric Rheumatology Online Journal, 2021
Background Subcutaneous anakinra is an interleukin-1 inhibitor used to treat juvenile idiopathic arthritis. Recent reports suggest anakinra can be a valuable addition to the treatment of COVID-19 associated cytokine storm syndrome and the related ...
Omkar Phadke, Kelly Rouster-Stevens, Helen Giannopoulos, Shanmuganathan Chandrakasan, Sampath Prahalad   +4 more
doaj   +1 more source